2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendationsLes lignes directrices canadiennes 2009 de la Société canadienne de cardiologie pour le diagnostic et le traitement de la dyslipidémie ainsi que pour la prévention des maladies cardiovasculaires chez l’adulte – Des recommandations pour 2009

https://doi.org/10.1016/S0828-282X(09)70715-9Get rights and content

The present article represents the 2009 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult.

Le présent article contient la mise à jour 2009 des lignes directrices de la Société canadienne de cardiologie pour le diagnostic et le traitement de la dyslipidémie et pour la prévention des maladies cardiovasculaires chez l’adulte.

References (79)

  • A.S. Kini et al.

    Relation of high-density lipoprotein cholesterol to mortality after percutaneous coronary interventions in patients with low-density lipoprotein <70 mg/dl

    Am J Cardiol

    (2009)
  • P.M. Ridker et al.

    Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial

    Lancet

    (2009)
  • J.H. Stein et al.

    American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: A consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine

    J Am Soc Echocardiogr

    (2008)
  • K. Alrasadi et al.

    Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g)

    Am J Cardiol

    (2008)
  • Heart and Stroke Foundation of Canada. The Growing Burden of Heart Disease and Stroke in Canada 2003....
  • Statistics Canada. CANSIM. <http://cansim2.statcan.ca>(Version current at August 13,...
  • P.M. Ridker et al.

    Non-HDL cholesterol, apolipoproteins A-I and B-100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women

    JAMA

    (2005)
  • P.M. Ridker et al.

    Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

    N Engl J Med

    (2008)
  • D.M. Lloyd-Jones et al.

    Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults – a prospective study of parents and offspring

    JAMA

    (2004)
  • Y. Friedlander et al.

    Family history as a risk factor for primary cardiac arrest

    Circulation

    (1998)
  • J.P. Després et al.

    Abdominal obesity and metabolic syndrome

    Nature

    (2006)
  • P.T. Katzmarzyk et al.

    Prevalence of class I, II and III obesity in Canada

    CMAJ

    (2006)
  • M.M. Ward

    Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus

    Arthritis Rheum

    (1999)
  • D.D. Gladman et al.

    Cardiovascular morbidity in psoriatic arthritis

    Ann Rheum Dis

    (2009)
  • C.M. Thorburn et al.

    Hospitalizations for coronary artery disease among patients with systemic lupus erythematosus

    Arthritis Rheum

    (2003)
  • S.D. Dorn et al.

    Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: Results from a systematic review and meta-analysis

    Am J Gastroenterol

    (2007)
  • N. Friis-Møller et al.

    Class of antiretroviral drugs and the risk of myocardial infarction

    N Engl J Med

    (2007)
  • C. Baigent et al.

    Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

    Lancet

    (2005)
  • The SEARCH Study. <http://www.ctsu.ox.ac.uk/∼search/>(Version current at August 13,...
  • E.S. Ford et al.

    Explaining the decrease in U.S. deaths from coronary disease, 1980–2000

    N Engl J Med

    (2007)
  • E. Lonn et al.

    Homocysteine lowering with folic acid and B vitamins in vascular disease

    N Engl J Med

    (2006)
  • S.C. Smith et al.

    AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the National Heart, Lung, and Blood Institute

    Circulation

    (2006)
  • A.S. Go et al.

    Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

    N Engl J Med

    (2004)
  • M.J. Sarnak et al.

    Kidney disease as a risk factor for development of cardiovascular disease – a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention

    Circulation

    (2003)
  • G. Barbaro et al.

    Metabolic syndrome associated with HIV and highly active antiretroviral therapy

    Curr Diab Rep

    (2009)
  • P.M. Ridker et al.

    C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events

    Circulation

    (2003)
  • J. Danesh et al.

    Lipoprotein(a) and coronary heart disease – meta-analysis of prospective studies

    Circulation

    (2000)
  • M.H. Davidson et al.

    Consensus panel recommendation for incorporating lipoprotein associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines

    Am J Cardiol

    (2008)
  • G.L. Myers et al.

    National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Emerging biomarkers for primary prevention of cardiovascular disease

    Clin Chem

    (2009)
  • Cited by (0)

    View full text